Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Marios Nikolaidis et al.
Summary: Research has shown that coronaviruses have a strong ability for intergenomic recombination, where they can exchange genetic material not only within the same subgenus but also across different CoV genera, other viruses, and even hosts. These events often occur at double crossovers surrounding the Spike ORF, indicating the instability and mobility of this genomic region.
MOLECULAR BIOLOGY AND EVOLUTION
(2022)
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.
Article
Biochemistry & Molecular Biology
Henning Gruell et al.
Summary: This study demonstrates that neutralization of the SARS-CoV-2 Omicron variant is greatly reduced in individuals who received two doses of the COVID-19 vaccine or have recovered from the disease, but is significantly increased after a booster vaccine dose.
Review
Virology
Grigorios D. Amoutzias et al.
Summary: This review discusses the evolution of the coronavirus subfamily and its importance for human and animal health. The impact of point mutations, insertions/deletions, and recombination events on the evolution of coronaviruses is highlighted. The potential direction for the development of next-generation vaccines and the future evolutionary path of SARS-CoV-2 and the COVID-19 pandemic are also discussed.
Article
Biology
Eric Kowarz et al.
Summary: A global vaccination campaign is underway to immunize billions of people against the COVID-19 pandemic. However, rare cases of severe side effects, such as cerebral venous sinus thrombosis (CVST), have been reported after vaccination with adenoviral vector-based vaccines. These events have not been observed with mRNA-based vaccines. Scientists have proposed a mechanism called vaccine-induced immune thrombotic thrombocytopenia (VITT) and discovered that DNA-encoded Spike protein can be spliced in a way that leads to the secretion of potentially harmful Spike variants. Avoiding such splicing events is important for the safety of future vaccines.
Article
Medicine, General & Internal
Tal Patalon et al.
Summary: This study demonstrated that receiving a booster dose of the BNT162b2 vaccine can reduce the odds of testing positive for SARS-CoV-2 in the short term, potentially counteracting waning immunity. Further monitoring is needed to determine the duration of immunity following the booster dose.
JAMA INTERNAL MEDICINE
(2022)
Review
Immunology
Parisa Ghasemiyeh et al.
Summary: It has been 20 months since the detection of COVID-19 cases in Wuhan, China, which rapidly spread worldwide and led to a pandemic. Different therapeutic options have been considered, but challenges remain in treating moderate to severe cases and those with underlying conditions. Public vaccination is believed to be the most efficient strategy to control morbidity and mortality.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Editorial Material
Biochemistry & Molecular Biology
Jennifer A. Juno et al.
Article
Biochemistry & Molecular Biology
Rachna T. Shroff et al.
Summary: Cancer patients showed diminished immune responses to the BNT162b2 mRNA vaccine compared to the control group, but a third dose of the vaccine was found to be safe and significantly improved humoral immunity against SARS-CoV-2.
Letter
Medicine, General & Internal
Saman Saadat et al.
Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.
Article
Medicine, General & Internal
Ivan F N Hung et al.
Article
Multidisciplinary Sciences
Steven A. Kemp et al.
Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.
Article
Infectious Diseases
Massimo Fabiani et al.
Summary: A study conducted in Italy showed that the BioNTech/Pfizer COVID-19 vaccine has an effectiveness of 84% and 95% in preventing SARS-CoV-2 infection within certain time intervals, supporting ongoing vaccination campaigns with targeted communication.
Article
Infectious Diseases
Sathyavani Subbarao et al.
Letter
Medicine, General & Internal
Venkata Viswanadh Edara et al.
Summary: This study investigates the neutralizing antibody response to 4 SARS-CoV-2 variants in individuals who have been infected or vaccinated.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Letter
Hematology
Kamran Kadkhoda
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.
Article
Medicine, General & Internal
Katherine R. W. Emary et al.
Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.
Article
Medicine, General & Internal
Andreas Greinacher et al.
Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Angela Choi et al.
Summary: The study demonstrates that both the mRNA-1273 COVID-19 vaccine and its variant-modified booster doses are safe and effective in improving neutralizing antibody titers against various virus variants.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Virology
Noton K. Dutta et al.
JOURNAL OF VIROLOGY
(2020)
Review
Biotechnology & Applied Microbiology
Kenneth Lundstrom
FRONTIERS IN GENOME EDITING
(2020)
